Patents by Inventor Dan Frenkel
Dan Frenkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230053258Abstract: Isolated anti-IDE antibodies are provided. Each of the antibodies comprise an antigen recognition domain comprising the indicated CDR amino acid sequences. Methods of producing same, methods of using same, pharmaceutical compositions comprising same and articles of manufacture are also provided.Type: ApplicationFiled: December 10, 2020Publication date: February 16, 2023Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Itai BENHAR, Limor NAHARY, Dan FRENKEL, Ofir FURSHT, Yuval NASH, Mirit LIRAN
-
Publication number: 20220306710Abstract: A method of treating Alzheimer's Disease (AD) is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which prevents the binding of amyloid precursor protein (APP) to Tau protein.Type: ApplicationFiled: May 19, 2022Publication date: September 29, 2022Applicants: Yeda Research and Development Co. Ltd., Ramot at Tel-Aviv University Ltd.Inventors: Ruth ARNON, Ruth MARON, Gad ARMONY, Michael Menachem TSOORY, Meir WILCHEK, Dan FRENKEL
-
Patent number: 9757448Abstract: Methods for treating and reducing risk of cerebral amyloid angiopathy (CAA) using nasal vaccination with a proteosome adjuvant.Type: GrantFiled: February 24, 2011Date of Patent: September 12, 2017Assignees: The Brigham and Women's Hospital, Inc., Ramot At Tel Aviv University Ltd.Inventors: Howard Weiner, Dan Frenkel, Veronica Lifshitz
-
Patent number: 9649507Abstract: Methods and systems are provided for delivering visible or infrared biostimulatory energy to bone marrow to subjects having or developing Alzheimer's disease. The radiation is delivered to sites remote from the brain at a dose sufficient to cause stimulated mesenchymal stem cells to appear in the brain and degrade ?-amyloid. The energy may be coherent light and can be administered transcutaneously, subcutaneously, or via an intramedullary probe.Type: GrantFiled: July 20, 2016Date of Patent: May 16, 2017Assignee: RAMOT AT TEL AVIV UNIVERSITY LTD.Inventors: Uri Oron, Hana Tuby, Dan Frenkel, Dorit Farfara
-
Publication number: 20160325115Abstract: Methods and systems are provided for delivering visible or infrared biostimulatory energy to bone marrow to subjects having or developing Alzheimer's disease. The radiation is delivered to sites remote from the brain at a dose sufficient to cause stimulated mesenchymal stem cells to appear in the brain and degrade ?-amyloid. The energy may be coherent light and can be administered transcutaneously, subcutaneously, or via an intramedullary probe.Type: ApplicationFiled: July 20, 2016Publication date: November 10, 2016Inventors: Uri Oron, Hana Tuby, Dan Frenkel, Dorit Farfara
-
Patent number: 9403030Abstract: Methods and systems are provided for delivering visible or infrared biostimulatory energy to bone marrow to subjects having or developing Alzheimer's disease. The radiation is delivered to sites remote from the brain at a dose sufficient to cause stimulated mesenchymal stem cells to appear in the brain and degrade ?-amyloid. The energy may be coherent light and can be administered transcutaneously, subcutaneously, or via an intramedullary probe.Type: GrantFiled: March 25, 2012Date of Patent: August 2, 2016Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Uri Oron, Hana Tuby, Dan Frenkel, Dorit Farfara
-
Patent number: 8901074Abstract: An insulin degrading enzyme (IDE) inhibitor for use in the treatment of a disease selected from the group consisting of an autoimmune disease of the central nervous system and a neurodegenerative disease is disclosed.Type: GrantFiled: August 4, 2011Date of Patent: December 2, 2014Assignee: Ramot at Tel-Aviv UniversityInventors: Dan Frenkel, Hilit Levy, Nofit Borenstein, Dorit Farfara, Dorit Trudler
-
Patent number: 8691760Abstract: Use of an isolated peptide comprising an amino acid sequence being no more than 25 amino acids in length, the amino acid sequence comprising at least one aspartate or a homolog thereof, the peptide having an Insulin-Degrading Enzyme (IDE) inhibitory activity, for the manufacture of a medicament identified for treating a disease selected from the group consisting of diabetes, obesity, hyperglycemia, retinal damage, renal failure, nerve damage, microvascular damage and varicella-zoster virus (VZV) infection is disclosed.Type: GrantFiled: February 2, 2010Date of Patent: April 8, 2014Assignee: Ramot at Tel-Aviv UniversityInventors: Dan Frenkel, Adi Kopelevich, Veronica Lifshitz, Tali Benromano, Nofit Borenstein
-
Publication number: 20140039581Abstract: Methods and systems are provided for delivering visible or infrared biostimulatory energy to bone marrow to subjects having or developing Alzheimer's disease. The radiation is delivered to sites remote from the brain at a dose sufficient to cause stimulated mesenchymal stem cells to appear in the brain and degrade ?-amyloid. The energy may be coherent light and can be administered transcutaneously, subcutaneously, or via an intramedullary probe.Type: ApplicationFiled: March 25, 2012Publication date: February 6, 2014Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Uri Oron, Hana Tuby, Dan Frenkel, Dorit Farfara
-
Publication number: 20130183245Abstract: Methods for treating and reducing risk of cerebral amyloid angiopathy (CAA) using nasal vaccination with a proteosome adjuvant.Type: ApplicationFiled: February 24, 2011Publication date: July 18, 2013Applicants: TEL AVIV UNIVERSITY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Howard Weiner, Dan Frenkel, Veronica Lifshitz
-
Publication number: 20130130976Abstract: An insulin degrading enzyme (IDE) inhibitor for use in the treatment of a disease selected from the group consisting of an autoimmune disease of the central nervous system and a neurodegenerative disease is disclosed.Type: ApplicationFiled: August 4, 2011Publication date: May 23, 2013Inventors: Dan Frenkel, Hilit Levy, Nofit Borenstein, Dorit Farfara, Dorit Trudler
-
Publication number: 20120028894Abstract: Use of an isolated peptide comprising an amino acid sequence being no more than 25 amino acids in length, the amino acid sequence comprising at least one aspartate or a homolog thereof, the peptide having an Insulin-Degrading Enzyme (IDE) inhibitory activity, for the manufacture of a medicament identified for treating a disease selected from the group consisting of diabetes, obesity, hyperglycemia, retinal damage, renal failure, nerve damage, microvascular damage and varicella-zoster virus (VZV) infection is disclosed.Type: ApplicationFiled: February 2, 2010Publication date: February 2, 2012Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Dan Frenkel, Adi Kopelevich, Veronica Lifshitz, Tali Benromano, Nofit Borenstein
-
Publication number: 20100144868Abstract: Disclosed are novel hybrid compounds having a fullerene core residue, one or more bioavailability enhancing moieties and one or more glutamate receptor ligand residues, whereby the bioavailability enhancing moiety allow the compound to reach an effective concentration in physiological media and pass the blood-brain barrier, as defined in the specification. Also disclosed are pharmaceutical compositions containing these hybrid compounds and uses thereof as antioxidants and/or neuroprotective agents for the treatment of medical conditions associated with oxidative stress and/or neural damage, such as, for example, neurological diseases, disorders and trauma, and hence in the treatment of CNS-associated diseases, disorders and trauma, as well as to uses thereof as antiviral, antibacterial, antiglycemic, antiarrhythmic, antidepressant and antitumor agents.Type: ApplicationFiled: January 22, 2006Publication date: June 10, 2010Applicants: Ramot At Aviv University Ltd., The Brigham and Women's Hospital Inc.Inventors: Michael Gozin, Howard L. Weiner, Alon Monsonego, Amnon Bar-Shir, Yoni Engel, Dan Frenkel
-
Publication number: 20080241169Abstract: A strategy for immunizing against amyloid plaques using display technology. The strategy includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antigen or epitope on a display vehicle. The strategy further includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, desegregation of plaques results from the immunization.Type: ApplicationFiled: October 29, 2007Publication date: October 2, 2008Applicant: Ramot at Tel-Aviv University, Ltd.Inventors: Beka SOLOMON, Dan Frenkel
-
Publication number: 20060229233Abstract: Compositions useful for treating neurological disorders including neurodegenerative disorders associated with deleterious protein aggregation, aberrant protein folding, such as brain amylogenic diseases, and/or neurodegenerative autoimmune disorders are described. Methods of using said compositions also are described. In particular, methods to treat a neurodegenerative disorder such as Alzheimer's disease and a neurodegenerative autoimmune disorder such as Multiple Sclerosis are contemplated utilizing proteosomes and/or Glatiramer Acetate, wherein the GA is in a submicron emulsion or a nanoemulsion.Type: ApplicationFiled: June 27, 2005Publication date: October 12, 2006Applicants: ID Biomedical Corporation, Brigham and Womens's HospitalInventors: Dan Frenkel, Ruth Maron, David Burt, Howard Weiner
-
Patent number: 6919075Abstract: A method of immunizing against plaque forming diseases using display technology is provided. The method utilize novel agents, or pharmaceutical compositions for vaccination against plaque forming diseases which rely upon presentation of an antigen or epitope on a display vehicle. The method further includes agents, or pharmaceutical compositions for vaccination against plaque forming diseases, which rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, disaggregation of plaques results from the immunization.Type: GrantFiled: August 31, 2000Date of Patent: July 19, 2005Assignee: Ramot at Tel Aviv University Ltd.Inventors: Beka Solomon, Dan Frenkel, Eilat Hanan
-
Publication number: 20050152878Abstract: A method of immunizing against plaque forming diseases using display technology is provided. The method utilizes novel agents, or pharmaceutical compositions for vaccination against plaque forming diseases that rely upon presentation of an antigen or epitope on a display vehicle. The method further includes agents, or pharmaceutical compositions for vaccination against plaque forming diseases, which rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, disaggregation of plaques results from the immunization.Type: ApplicationFiled: March 8, 2005Publication date: July 14, 2005Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Beka Solomon, Dan Frenkel, Eilat Hanan
-
Publication number: 20050089510Abstract: A method of immunizing against plaque forming diseases using display technology is provided. The method utilize novel agents, or pharmaceutical compositions for vaccination against plaque forming diseases which rely upon presentation of an antigen or epitope on a display vehicle. The method further includes agents, or pharmaceutical compositions for vaccination against plaque forming diseases, which rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, disaggregation of plaques results from the immunization.Type: ApplicationFiled: January 2, 2004Publication date: April 28, 2005Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Beka Solomon, Eilat Hanan, Dan Frenkel
-
Publication number: 20040052766Abstract: A strategy for immunizing against amyloid plaques using display technology. The strategy includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antigen or epitope on a display vehicle. The strategy further includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, desegregation of plaques results from the immunization.Type: ApplicationFiled: July 15, 2003Publication date: March 18, 2004Applicant: Ramot at Tel-Aviv University, Ltd.Inventors: Beka Solomon, Dan Frenkel
-
Patent number: 6703015Abstract: A strategy for immunizing against amyloid plaques using display technology. The strategy includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g. Alzheimer's disease) which rely upon presentation of an antigen or epitope on a display vehicle. The strategy further includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g. Alzheimer's disease) which rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, desegregation of plaques results from the immunization.Type: GrantFiled: December 29, 1999Date of Patent: March 9, 2004Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Beka Solomon, Dan Frenkel